Date Title Description PDF
26 Jul 2023 On P&L The Company releases the press release related to the first half 2023 financial results Download
26 Jul 2023 On P&L The Company releases the first half 2023 financial results presentation Download
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download

Pages

Date Title Description PDF
08 May 2024 Announcement of General Shareholders’ Meeting The Company announces the decision of its Board of Directors to convene the Ordinary General Shareholders' Meeting Download
30 Apr 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 26 April and 30 April 2024 Download
26 Apr 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 19 April and 25 April 2024 Download
19 Apr 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 12 April and 18 April 2024 Download
12 Apr 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 5 April and 11 April 2024 Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages